Status:
WITHDRAWN
Effects of IL-1β and Its Receptor Antagonists in the Treatment of Severe Infection and Inflammatory Storm in Children
Lead Sponsor:
Children's Hospital of Fudan University
Conditions:
Critical Illness
Sepsis, Severe
Eligibility:
All Genders
29-18 years
Brief Summary
In severe infective patients who survive the initial inflammatory storm, the immune response often evolves toward a state of immunosuppression, which contributes to increased mortality and severe seco...
Detailed Description
The investigators intend to enroll all children who were hospitalized in pediatric intensive care unit of Children's Hospital of Fudan University from January 2022 to December 2023. Children with a PI...
Eligibility Criteria
Inclusion
- Children between 29 days and 18 years old.
- Severe pneumonia and/or sepsis.
- Patients were included who meet the guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019) issued by the National Health Commission of the people's Republic of China and/or who meet the International Guide to the 2020 campaign to Save sepsis: management of septic shock and sepsis-related organ dysfunction in children.
Exclusion
- Notifiable infectious diseases.
- The researcher believes that he is not suitable to participate in other situations in this study.
- Participants in other clinical trials in the same period.
- Discharge within 48 hours
Key Trial Info
Start Date :
September 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04821414
Start Date
September 1 2022
End Date
December 31 2024
Last Update
June 15 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.